Group 1 - The company held its 19th temporary board meeting on May 30, 2025, with all 9 directors present, and the meeting complied with relevant laws and regulations [1][2][3] - The board approved the proposal to change the legal representative from Chairman Xiao Wei to Director Gao Haixin, which aligns with the Company Law and the company's articles of association [1][3] - The board authorized relevant personnel to handle the business registration change in accordance with regulations [3] Group 2 - The company completed the repurchase and cancellation of all remaining restricted stocks from the 2022 incentive plan on May 29, 2025, reducing the total share capital from 569,459,106 shares to 566,158,806 shares [8][9] - Following the repurchase, the controlling shareholder, Jiangsu Kangyuan Group, saw its shareholding percentage increase from 30.94% to 31.12% without changing the number of shares held [8][10] - This change in shareholding percentage is due to the repurchase and does not affect the company's controlling shareholder or actual controller [10][11]

Group 1 - Jiangsu Kangyuan Pharmaceutical Commercial Co., Ltd. applied for a patent titled "A Method and Device for Drug Distribution," with publication number CN120071512A, filed on November 2024 [1] - The patent describes a drug distribution client that includes at least one processor and one memory, configured to send purchase requests to a drug distribution server and handle responses accordingly [1] - The invention aims to provide a convenient way for patients to address different needs for prescription and over-the-counter drugs during the purchasing process [1] Group 2 - Jiangsu Kangyuan Pharmaceutical Commercial Co., Ltd. was established in 1990, located in Lianyungang, with a registered capital of 136 million RMB [2] - The company has invested in 23 enterprises, participated in 332 bidding projects, and holds 2 patents along with 31 administrative licenses [2] - Jiangsu Kangyuan Pharmaceutical Co., Ltd. was founded in 1996, also in Lianyungang, with a registered capital of approximately 581.8 million RMB [2] - This company has invested in 15 enterprises, participated in 5000 bidding projects, and possesses 354 trademark records and 1042 patent records, along with 588 administrative licenses [2]

Core Viewpoint - Jiangsu Kangyuan Pharmaceutical Co., Ltd. completed the repurchase and cancellation of restricted stocks, resulting in a passive increase in the shareholding ratio of its controlling shareholder, Kangyuan Group, from 30.94% to 31.12% [1][2][3] Summary by Sections 1. Completion of Restricted Stock Repurchase - The company repurchased and canceled a total of 3,300,300 restricted stocks, reducing the total share capital from 569,459,106 shares to 566,158,806 shares [2] - The repurchase and cancellation were confirmed by China Securities Depository and Clearing Corporation Limited Shanghai Branch on May 29, 2025 [2] 2. Changes in Shareholding Ratios - Following the repurchase, Kangyuan Group's shareholding ratio increased from 30.94% to 31.12%, while the number of shares held remained unchanged at 176,173,467 shares [2] - Other shareholders, including Yin Ye Gong Yu No. 10 Private Securities Investment Fund, Mr. Xiao Wei, and Nanjing Kangzhu Enterprise Management Partnership, did not experience changes in their shareholding quantities [2] 3. Regulatory Compliance - The company will proceed with the necessary business registration changes following the completion of the stock repurchase and cancellation [2] - The announcement serves as a compliance measure for changes in shareholding ratios that touch upon 1% integer multiples [3]

Core Points - Jiangsu Kangyuan Pharmaceutical Co., Ltd. held its 19th temporary meeting of the 8th Board of Directors on May 30, 2025, to discuss and approve key resolutions [1][2] - The board approved a proposal to change the legal representative from Chairman Xiao Wei to Director Gao Haixin, which complies with relevant laws and regulations [1][2] - The voting results for the proposal were unanimous, with 9 votes in favor and no votes against or abstentions [1] Summary by Sections Board Meeting Details - The meeting was notified on May 28, 2025, and conducted both in-person and via communication methods [1] - The meeting was presided over by Chairman Xiao Wei [1] Legal Representative Change - The change of the legal representative is in accordance with the Company Law of the People's Republic of China and the Shanghai Stock Exchange's self-regulatory guidelines [1] - The board authorized relevant personnel to handle the business registration change as per regulations [2] Profile of New Legal Representative - Gao Haixin, born in May 1988, holds a doctoral degree and has been with the company since 2014, serving in various roles [4] - As of the announcement date, Gao Haixin holds 60,000 shares of the company and has no conflicts of interest with other board members or significant shareholders [4]

江苏康缘药业股份有限公司 关于公司控股股东因公司回购注销限制性股票 持股比例被动增加触及1%整数倍的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券简称：康缘药业 证券代码：600557 公告编号：2025-023 本次回购注销完成后，公司控股股东江苏康缘集团有限责任公司（以下 简称"康缘集团"）在持有公司的股份数量不变的情况下，持有公司股份比例 由 30.94%被动增加至 31.12%，适用权益变动触及 1%整数倍的情形。本次权益 变动不会导致公司控股股东及实际控制人发生变化。 江苏康缘药业股份有限公司已于 2025 年 5 月 29 日办理完成回购注销公司 2022 年度限制性股票激励计划剩余全部限制性股票事宜。本次回购注销导致公 司控股股东江苏康缘集团有限责任公司在持有公司的股份数量不变的情况下， 持有公司股份比例由 30.94%被动增加至 31.12%，适用权益变动触及 1%整数倍 的情形，具体情况如下。 一、本次限制性股票回购注销完成情况 公司本次回购注销的限制性股票数量为 330,03 万股，本次回 ...

证券简称：康缘药业 证券代码：600557 公告编号：2025-022 一、审议通过《关于变更法定代表人的议案》 公司董事会拟将法定代表人由董事长肖伟先生变更为代表公司执行公司事务的 董事高海鑫先生，该变更符合《中华人民共和国公司法》《上海证券交易所上市公 司自律监管指引》等法律法规以及康缘药业《公司章程》第八条的相关规定。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 董事会授权相关人员依规办理工商登记变更事宜，具体以工商行政管理部门登 记为准。 江苏康缘药业股份有限公司 第八届董事会第十九次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏康缘药业股份有限公司（以下简称"公司""康缘药业"）第八届董事会 第十九次临时会议通知于 2025 年 5 月 28 日以书面文件、电话和电子邮件方式发出， 会议于 2025 年 5 月 30 日在公司会议室以现场结合通讯方式召开。应出席会议董事 9 人，实际出席会议董事 9 人。本次会议的召开符合《公司法》等法律法规以及《公 司章程》的规定。会议由董事长肖伟 ...

Group 1 - Kangyuan Pharmaceutical has launched a significant generic drug, Sumatriptan Naproxen Sodium Tablets, which fills a gap in the domestic market as the original manufacturer has not yet received approval for entry [2] - The sales of neurological system drugs in China remain substantial, maintaining a scale of over 100 billion yuan, with analgesics holding a market share exceeding 17% [2] - This new drug is the third product approved for Kangyuan Pharmaceutical this year, alongside other products in the neurological field, including Piracetam Injection and Pirfenidone Tablets [2] Group 2 - Kangyuan Pharmaceutical is advancing its "one body, two wings" strategy, focusing on both traditional Chinese medicine and expanding into chemical and biological drugs [2][3] - The company has made significant progress in chemical drug development, particularly in antiviral and anti-tumor areas, enhancing its product matrix [2] - In 2024, Kangyuan Pharmaceutical will complete the acquisition of 100% of Zhongxin Pharmaceutical, which specializes in the development of recombinant human cytokines and antibody biological drugs, further solidifying its growth strategy [3]

Core Insights - In 2024, the company expects a decline in both revenue and net profit, with projected figures of 3.898 billion and 392 million respectively, representing year-on-year decreases of 19.86% and 15.58% [1] - The first quarter of 2024 continues to show pressure on performance, with revenue of 878 million, down 35.38% year-on-year, and net profit of 83.41 million, down 38.37% [1] - The decline in first-quarter revenue is primarily attributed to a decrease in sales of the core injection product, Heat Toxicity Ning Injection [1][2] Product Performance - The core injection products have historically driven high growth, with Heat Toxicity Ning Injection sales exceeding 1 billion in 2013, but experiencing significant fluctuations due to policy changes [2] - The 2023 National Medical Insurance Directory allowed for increased sales of Heat Toxicity Ning Injection, reaching 6.077 million units, but sales fell to 4.195 million units in 2024, with inventory levels increasing by 759.11% [2] - Ginkgo Biloba Diterpene Amine Injection has also contributed to revenue growth, but its price dropped significantly after negotiations, limiting its growth potential [3] - The company’s oral liquid product, Jin Zhen Oral Liquid, has shown inconsistent sales performance, with year-on-year changes of 74.81%, -22.67%, and 5.13% from 2022 to 2024 [3] Financial Overview - In the first quarter, the injection product category generated approximately 340 million in revenue, down 36.86% year-on-year [4] - The overall revenue for the company in the first quarter was 867.22 million, with a total revenue decline of 35.79% [7] - The company reported a significant decline in operating cash flow, down 59.9% to 77 million in the first quarter, raising concerns about balancing cash flow health with long-term investments [9] New Product Developments - The company has received approvals for several new traditional Chinese medicine products, but their contribution to overall revenue remains limited, with a 10.34% decline in revenue from granules and powders in 2024 [6] - The company has not disclosed sales figures for the "Scattering Cold and Dampness Granules," a product related to COVID-19 treatment, despite investor inquiries [8]

Core Viewpoint - Jiangsu Kangyuan Pharmaceutical Co., Ltd. has decided to repurchase and cancel a total of 3.3003 million restricted stocks from 155 incentive recipients due to unmet performance assessment criteria for the fiscal year 2024 [2][5][8] Group 1: Reasons for Repurchase and Cancellation - The repurchase and cancellation of restricted stocks are based on the failure to meet the performance assessment conditions outlined in the 2022 Restricted Stock Incentive Plan [4][5] - The specific conditions for lifting the restrictions included a revenue growth rate of no less than 18% or a net profit growth rate of no less than 20% for 2024, which were not achieved [4][5] - The company reported a revenue of 389.77 million yuan for 2024, a decrease of 19.86% year-on-year, and a net profit of 39.19 million yuan, down 15.58% year-on-year [5] Group 2: Details of the Repurchase and Cancellation - The decision to repurchase was approved in the board and supervisory meetings held on April 2, 2025, and the relevant announcements were disclosed on April 3, 2025 [3][4] - The repurchase will be executed through a dedicated securities account, with the cancellation expected to be completed by May 29, 2025 [6] - After the cancellation, the 2022 Restricted Stock Incentive Plan will be fully concluded [8] Group 3: Legal and Compliance Aspects - The company has ensured that the decision-making process and information disclosure comply with relevant laws and regulations, including the Management Measures for Equity Incentives [9][10] - A legal opinion has confirmed that the necessary authorizations and approvals for the repurchase and cancellation have been obtained [10]

证券简称：康缘药业 证券代码：600557 公告编号：2025-021 江苏康缘药业股份有限公司 关于公司2022年度限制性股票激励计划剩余 全部限制性股票回购注销实施的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 回购注销原因 鉴于江苏康缘药业股份有限公司（以下简称"公司"）2024 年度公司层面考 核条件未达标，公司 2022 年度限制性股票激励计划首次授予及预留部分首批授 予第三个解除限售期、预留部分第二批授予第二个解除限售期解除限售条件未成 就，根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、公司 《2022 年度限制性股票激励计划（更正后）》（以下简称"《激励计划》"或 "本次激励计划"）的规定及 2021 年年度股东大会的授权，公司决定将上述涉 及的 155 名激励对象已获授但尚未解除限售的限制性股票共计 330.03 万股进行 回购注销。 本次注销股份的有关情况 | 回购股份数量（股） | 注销股份数量（股） | 注销日期 | | | | --- | --- | --- ...